EyePoint reports positive Phase 2 DAVIO 2 topline for EYP-1901 in wet AMD; all endpoints met

EyePoint, Inc.

Both EYP-1901 doses (2mg and 3mg) achieved non-inferiority in BCVA vs aflibercept (difference of -0.3 and -0.4 letters).
Over 80% reduction in treatment burden; 65%/64% of eyes supplement-free up to six months for 2mg/3mg.
No EYP-1901-related ocular or systemic SAEs; favorable safety profile.
Phase 3 pivotal trial for wet AMD planned for H2 2024; DME trial starts Q1 2024; NPDR data Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.